Open Access
Subscription Access
Open Access
Subscription Access
Computational Approach for the Design of Flavone based CDK2/CyclinA Inhibitors:A Simulation Study Employing Pharmacophore based 3D QSAR
Subscribe/Renew Journal
The present work aimed at designing selective and potent inhibitors of CDK2/CyclinA as anticancer agents. A five point pharmacophore (AAADR) model was developed for the reported molecules from literature, the pharmacophore model was used to build predictive 3D QSAR equation. The selected 3D QSAR models revealed the importance of hydrogen bond acceptors, hydrogen bond donors and aromatic rings for selectively towards the target enzyme. The developed models were statistically robust (CDK2/Cyclin A, Q2- 0.6380, R2 value of 0.9857, SD-0.1667, F-320.9 and Pearson coefficient value of 0.7916). The built model could be useful for the design and development of novel and selective inhibitors of CDK2/Cyclin A.
Keywords
Flavopiridol, CDK, QSAR, Pharmacophore, GLIDE, Docking.
Subscription
Login to verify subscription
User
Font Size
Information
- J.W. Harper, P.D. Adams, Chem. Rev. 101 (2001) 2511.
- M. Mihara, S. Shintani, A. Kiyota, T. Matsumura, D.T.W. Wong, Int. J. Oncol. 21(2002) 95.
- Sielecki, T. M.; Boylan, J. F.; Benfiled, P. A.; Trainor, G. T. J. Med. Chem. 2000, 43, 1; (b) Toogood, P. I. Med. Res. Rev. 2001, 21, 487; (c) Hirai, H.; Kawanishi, N., Iwasawa, Y. Curr. Top. Med. Chem. 2005, 5, 167.
- Morgan, D. O. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu. ReV. Cell DeV. Biol. 1997, 13, 261-291.
- Sherr, C. J. Cancer cell cycles. Science 1996, 274, 1672-1677.
- Nurse, P.; Masui, Y.; Hartwell, L. Nat. Med. 1998, 4, 1103-1106.
- Fischer, P. M. Cell Cycle 2004, 3, 742-746.
- Senderowicz AM. Cyclin-dependent kinases as targets for cancer therapy. In Giaccone G, Schilsky R, Sondel P, editors. Cancer chemotherapy and biological response modifiers, annual 20. Elsevier Science; 2002. p. 169–88.
- Losiewicz MD, Carlson BA, Kaur G, Sausville EA, Worland PJ. Potent inhibition of cdc2 kinase activity by the flavonoid L868275. Biochem Biophys Res Commun1994;201:589–95.
- Carlson BA, Dubay MM, Sausville EA, Brizuela L, WorlandPJ. Flavopiridol induces G1 arrest with inhibition of cyclindependent kinase CDC2 and CDK4 in human breast carcinoma cells. Cancer Res 1996;56:2973–8.
- Carlson BA, Pearlstein RA, Naik RG, Sedlacek HH, Sausville EA, Worland PJ. Inhibition of CDK2, CDK4 and CDK7 by flavopiridol and structural anologs. In: Proceedings of the American Association of Cancer Research. 1996.
- Dumant, JA, HMR Report No. B/98/0189/R,B/98/0188/R,8/98/0187/R. HMR Oncology, 1996.
- Cartee L, Wang Z, Decker RH, Chellappan SP, Fusaro G, Hirsch KG, et al. The Cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate13-acetate-induced differentiation and CDKI Expression while enhancing apoptosis in human myeloid leukemia cells. Cancer Res 2001;61(6):2583– 91.
- Konig A, Schwartz GK, Mohammad RM, et al. The novel cyclindependent kinase inhibitor flavopiridol down regulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia cell lines. Blood1997;90:4307–12.
- Motwani M, Jung C, Sirotnak FM, She Y, Shah MA, Gonen M, et al. Augmentation of apoptosis and tumor regressions by flavopiridol in the presence of CPT-11 in HCT116 coloncancer monolayers and xenografts. Clin Cancer Res2001;7:4209–19.
- Carlson B, Lahusen T, Singh S, Loaiza-Perez A, Worland PJ, Pestell R, et al. Down-regulation of cyclin D1 bytranscriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res1999;59(18):4634–41.
- Wall NR, O’Connor DS, Plescia J, Pommier Y, Altieri DC. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res 2003;63:230–5 18. Motwani MV, Sirotnak F, She Y, Commes T, Schwartz GK. Anovel target for modulating sensitivity to CPT-11 in colon cancer cells. Cancer Res 2002; 62:3950–5.
- Shah MA, Kortmansky J, Motwani M, Drobjnak M, Gonen M, Yi S, et al. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin Cancer Res 2005; 11(10):3836–45.
- Shapiro GI, Patterson A, Lynch C, et al. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res 2001; 7(6):1590–9.
- Schwartz GK, Ilson D, Saltz L, O’Reilly E, Tong W, Maslak P, et al. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J ClinOncol2001; 19(7):1985–92.
- Stadler WM, Vogelzang NJ, Amato R, Sosman J, Taber D, Liebowitz D, et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium Study. J ClinOncol2000;18(2):371–5
- Burdette-Radoux S, Tozer RG, Lohmann R, et al. NCIC CT Gnphase II study of flavopiridol in patients with previously untreated metastatic malignant melanoma. In: Proc Am Soc Clin Oncol. 2002.
- Aklilu M, Kindler HL, Donehower RC, Mani S, Vokes EE. Phase II study of flavopiridol in patients with advanced colorectal cancer. Ann Oncol 2003;14(8):1270
- Lin T, Dalton JT, Wu B, et al. Flavopiridol given as a 30minute intravenous (IV) bolus followed by 4-hr continuous IV infusion results in clinical activity and tumor lysis in refractory chronic lymphocytic leukemia. Proc ASCO2004; 23:571 [abstract #6564].
- Schoepfer, Joseph, et al. "Structure-based design and synthesis of 2-benzylidene-benzofuran-3-ones as flavopiridol mimics." Journal of medicinal chemistry 45.9 (2002): 1741-1747.
- Ahn, Yu Mi, et al. "Design, synthesis, and antiproliferative and CDK2-cyclin a inhibitory activity of novel flavopiridol analogues." Bioorganic & medicinal chemistry 15. 2 (2007): 702-713.
Abstract Views: 242
PDF Views: 0